TNKase

Cedars-Sinai Medical Center · FDA-approved active Small molecule

TNKase is a Fibrinolytic agent; tissue plasminogen activator (tPA) Small molecule drug developed by Cedars-Sinai Medical Center. It is currently FDA-approved for Acute myocardial infarction (STEMI) for restoration of coronary blood flow. Also known as: Tenecteplase, TNK.

TNKase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow in acute myocardial infarction.

TNKase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow in acute myocardial infarction. Used for Acute myocardial infarction (STEMI) for restoration of coronary blood flow.

At a glance

Generic name	TNKase
Also known as	Tenecteplase, TNK
Sponsor	Cedars-Sinai Medical Center
Drug class	Fibrinolytic agent; tissue plasminogen activator (tPA)
Target	Fibrin; plasminogen
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

TNKase (tenecteplase) is a genetically engineered variant of natural tissue plasminogen activator with enhanced fibrin specificity and longer half-life. It binds to fibrin in thrombi and catalyzes the conversion of plasminogen to plasmin, which degrades the fibrin matrix of blood clots. This fibrinolytic action rapidly restores coronary blood flow in patients experiencing acute ST-elevation myocardial infarction (STEMI).

Approved indications

• Acute myocardial infarction (STEMI) for restoration of coronary blood flow

Common side effects

• Bleeding (major and minor)
• Intracranial hemorrhage
• Hypotension
• Arrhythmias (reperfusion)
• Nausea/vomiting

Key clinical trials

• Neuronavigation-assisted Stereotactic Minimally Invasive Puncture With Tenecteplase for Acute Lobar Intracerebral Hemorrhage (PHASE3)
• Low-Dose Tenecteplase for Acute Ischemic Stroke Treatment in Aging Patients (PHASE4)
• Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO) (PHASE3)
• Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours (PHASE4)
• Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours (PHASE3)
• Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
• A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well (PHASE3)
• Unknown Time of Onset Stroke RePerfusIon Without Advanced Imaging (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• TNKase CI brief — competitive landscape report
• TNKase updates RSS · CI watch RSS
• Cedars-Sinai Medical Center portfolio CI

Frequently asked questions about TNKase

What is TNKase?

TNKase is a Fibrinolytic agent; tissue plasminogen activator (tPA) drug developed by Cedars-Sinai Medical Center, indicated for Acute myocardial infarction (STEMI) for restoration of coronary blood flow.

How does TNKase work?

TNKase is a tissue plasminogen activator (tPA) that converts plasminogen to plasmin, which breaks down fibrin clots to restore blood flow in acute myocardial infarction.

What is TNKase used for?

TNKase is indicated for Acute myocardial infarction (STEMI) for restoration of coronary blood flow.

Who makes TNKase?

TNKase is developed and marketed by Cedars-Sinai Medical Center (see full Cedars-Sinai Medical Center pipeline at /company/cedars-sinai-medical-center).

Is TNKase also known as anything else?

TNKase is also known as Tenecteplase, TNK.

What drug class is TNKase in?

TNKase belongs to the Fibrinolytic agent; tissue plasminogen activator (tPA) class. See all Fibrinolytic agent; tissue plasminogen activator (tPA) drugs at /class/fibrinolytic-agent-tissue-plasminogen-activator-tpa.

What development phase is TNKase in?

TNKase is FDA-approved (marketed).

What are the side effects of TNKase?

Common side effects of TNKase include Bleeding (major and minor), Intracranial hemorrhage, Hypotension, Arrhythmias (reperfusion), Nausea/vomiting.

What does TNKase target?

TNKase targets Fibrin; plasminogen and is a Fibrinolytic agent; tissue plasminogen activator (tPA).

Related

• Drug class: All Fibrinolytic agent; tissue plasminogen activator (tPA) drugs
• Target: All drugs targeting Fibrin; plasminogen
• Manufacturer: Cedars-Sinai Medical Center — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Acute myocardial infarction (STEMI) for restoration of coronary blood flow
• Also known as: Tenecteplase, TNK